Screening for pancreatic cancer in high-risk individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on screening individuals at high risk for pancreatic ductal adenocarcinoma, particularly those with hereditary conditions or chronic pancreatic diseases. It employs interventions such as endoscopic ultrasonography, magnetic resonance imaging, and laboratory examinations to detect the disease early. The aim is to improve early diagnosis and potentially increase survival rates by identifying the disease before it becomes advanced. The study is conducted in the Czech Republic, where the incidence of pancreatic cancer is rising.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* willing to participate in the study
* age 18+
* arms specific criteria:

A:

* chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis
* age 50+

B1:

* confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
* familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
* confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack

B2:

* confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/)
* at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)
* age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first

C:

* positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context
* age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members

Exclusion Criteria:

* Inability to undergo radical curative surgery for a pancreatic tumor.
* Inability to undergo scheduled imaging examinations.
* Incurable malignant cancer.

Where it's running

• Masaryk Memorial Cancer Institute
  Brno, Czechia Recruiting

Study contacts

• Study coordinator: Martina Lojova, Ph.D.
• Email: martina.lojova@mou.cz
• Phone: +420543136232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lipidica software to screen for pancreatic cancer in high-risk patients

  This study is testing a new software called Lipidica to see if it can help find pancreatic cancer earlier in people who are at high risk because of their genetics or family history.

  Recruiting at 15 sites Lipidica, a.s. · Prague, Czechia and 15 other locations · NCT06549725

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• Microbial pancreatic enzyme therapy versus porcine enzyme in chronic pancreatitis with exocrine pancreatic insufficiency

  This study tests whether a microbial (fungal) pancreatic enzyme product can work as well as the standard porcine enzyme in adults with chronic pancreatitis and PEI.

  Recruiting Phase 3 Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07697352

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.